Introduction
CJC-1295 without DAC, also referred to in the literature as modified GRF (1-29), is a synthetic growth hormone-releasing hormone analogue that has attracted considerable attention in endocrinology and peptide research. Its design draws directly on the body's own signalling peptides, which has made it a frequent subject of laboratory study. As that interest has grown, so has demand from professionals who want to buy CJC-1295 UK sources for experimental work. This article offers a factual overview of the compound's molecular background, its published research history, its legal standing in the United Kingdom, and the handling requirements laboratories typically observe. It is intended purely as background information for those evaluating the peptide for research.
Molecular Background
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, also known as growth hormone-releasing factor. The native hormone is a 44 amino acid peptide, and much of its biological activity resides within the first 29 amino acids, the fragment commonly written as GRF (1-29). CJC-1295 is a modified version of this 1-29 sequence, engineered with amino acid substitutions intended to increase stability and resistance to enzymatic breakdown, particularly by the enzyme dipeptidyl peptidase-IV.
An important distinction within the literature is the presence or absence of the Drug Affinity Complex, or DAC. The DAC version incorporates a linker that binds to serum albumin, substantially extending the molecule's residence time. The version without DAC lacks this linker and is therefore associated with a much shorter duration of activity, which is why it is often described as more closely resembling the body's natural pulsatile signalling pattern. In its research form, CJC-1295 without DAC is typically supplied as a lyophilised, or freeze-dried, white powder. These structural characteristics are routinely referenced in published work and shape how the compound is prepared and stored.
Published Research History
The development and study of CJC-1295 is well documented in the peer-reviewed literature. A foundational paper by Jetté and colleagues, published in the journal Endocrinology in 2005, described the identification of CJC-1295 as a long-lasting growth hormone-releasing factor analogue and examined its activity at the growth hormone-releasing factor receptor in rat models.
Human research followed shortly afterward. A study by Teichman and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 2006, investigated the pharmacokinetic profile and pharmacodynamic effects of CJC-1295 in healthy adults across randomised, placebo-controlled trials. In the same year and the same journal, Ionescu and Frohman published work examining how pulsatile growth hormone secretion behaved during continuous stimulation by the analogue. Additional research by Alba and colleagues appeared in the American Journal of Physiology in 2006, exploring once-daily administration of CJC-1295 in a growth hormone-releasing hormone knockout mouse model. Across this body of work, findings are reported within controlled clinical and animal study settings rather than as general health outcomes. Recurring themes include the molecule's documented influence on growth hormone and insulin-like growth factor signalling in experimental contexts, with the distinction between the DAC and non-DAC forms remaining central to how researchers interpret the literature.
UK Legal Status as a Research Compound
In the United Kingdom, CJC-1295 without DAC occupies the position of a research compound rather than an approved medicine. It has not been authorised or licensed as a medicinal product by the Medicines and Healthcare products Regulatory Agency, and it is not approved for human use. It is also not classified as a controlled substance under the Misuse of Drugs Act 1971, so it does not carry the restrictions applied to scheduled drugs.
This regulatory position is precisely why anyone who wishes to buy CJC-1295 UK must do so strictly for laboratory and research purposes. The compound cannot lawfully be marketed for human consumption, nor accompanied by medicinal or therapeutic claims, as doing so would bring it within the scope of the Human Medicines Regulations 2012. Researchers and organisations remain responsible for ensuring their own compliance with applicable laws. It is also worth noting that growth hormone-releasing hormone analogues appear on the World Anti-Doping Agency prohibited list, which is relevant to anyone working in or around competitive sport. This is general information and not legal advice.
Storage and Reconstitution Requirements
Proper handling preserves the integrity of the peptide and is an important consideration for any laboratory that chooses to buy CJC-1295 UK stock for research. In its lyophilised form, the powder is generally kept sealed in its original vial, protected from light, and stored frozen for long-term preservation, typically at around minus twenty degrees Celsius. Short-term refrigeration is often acceptable, while exposure to heat, moisture and direct light is avoided, as these conditions can compromise peptide stability.
When a research protocol calls for reconstitution, bacteriostatic or sterile water is commonly used as the solvent. The liquid is directed slowly against the inside wall of the vial rather than added directly onto the powder, and the vial is swirled gently instead of shaken, which helps protect the peptide structure. Once reconstituted, the solution is kept refrigerated and handled under appropriate aseptic conditions. These steps reflect standard laboratory practice for handling lyophilised peptides and relate solely to preparation and preservation.
Conclusion
CJC-1295 without DAC remains a compound of genuine scientific interest, supported by a clear body of literature published in recognised journals. For laboratories and researchers who decide to buy CJC-1295 UK, understanding its molecular profile, its documented research history, its legal classification and its correct storage requirements is essential to responsible work. Sourcing the peptide from a supplier that prioritises quality and transparency, and that supplies it clearly for research only, supports the integrity of any experimental programme.
All products at Peptidal are for research purposes only and not for human consumption.